Merck Kommanditgesellschaft auf Aktien
⚠️ High Risk
FEI: 3002806906 • Darmstadt, Hassia • GERMANY
FEI Number
3002806906
Location
Darmstadt, Hassia
Country
GERMANYAddress
Frankfurter Str. 250, , Darmstadt, Hassia, Germany
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
NUTRIT LBL
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information.
DRUG NAME
The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
NO ENGLISH
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 11/21/2025 | 62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/20/2024 | 62ODY18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/16/2024 | 62ODB18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/28/2023 | 66JAY01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/28/2023 | 66JAY01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/24/2023 | 60LBC01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/24/2023 | 66JDC01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/13/2023 | 66PAS99ULTRAVIOLET SCREEN/SUNSCREEN N.E.C. | 118NOT LISTED | Division of Southeast Imports (DSEI) |
| 11/10/2022 | 55RP99PHARMACEUTIC NECESSITIES, N.E.C. | 118NOT LISTED | Division of Southeast Imports (DSEI) |
| 8/26/2022 | 66JCC01LEVOTHYROXINE SODIUM (THYROID HORMONE) | Division of Southeast Imports (DSEI) | |
| 4/10/2022 | 66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/22/2022 | 64MDB13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/10/2022 | 64MDY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/10/2022 | 64MCY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/3/2022 | 64MCY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/11/2022 | 64MDL13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/6/2022 | 64MCY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/1/2022 | 60SCH99ANTACID, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/20/2021 | 66JCY01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/16/2021 | 62ODA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/8/2021 | 64RDY21SOMATROPIN (HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/29/2021 | 64MDY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/27/2020 | 66JAB01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/15/2020 | 66JDY01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/10/2020 | 66JCY01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/16/2020 | 62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/2/2020 | 62ODY18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/29/2020 | 62OCB18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/18/2020 | 62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 5/12/2020 | 62OCB18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 3280FRNMFGREG | Division of Southeast Imports (DSEI) |
| 3/27/2020 | 66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/26/2019 | 64MCY07FOLLISTIM (FOLLITROPIN BETA(RDNA)) (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/1/2018 | 61PDY55METFORMIN HCL (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/8/2018 | 62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/14/2016 | 66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 7/28/2016 | 62WAS14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT) | Philadelphia District Office (PHI-DO) | |
| 7/28/2016 | 62ODA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 7/28/2016 | 61XCY15DEXBROMPHENIRAMINE MALEATE (ANTI-HISTAMINIC) | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 5/10/2016 | 62WBL14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT) | Philadelphia District Office (PHI-DO) | |
| 5/10/2016 | 62WBL14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT) | Philadelphia District Office (PHI-DO) | |
| 5/10/2016 | 62WBL14ZINC SULFATE ASTRINGENT/ANTI-PERSPIRANT) | Philadelphia District Office (PHI-DO) | |
| 3/17/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | Florida District Office (FLA-DO) |
| 3/17/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | Florida District Office (FLA-DO) |
| 3/10/2016 | 64XAR04RESORCINOL (KERATOLYTIC) | Division of Northeast Imports (DNEI) | |
| 3/10/2016 | 65TAR04SULFUR (SCABICIDE) | Division of Northeast Imports (DNEI) | |
| 2/1/2016 | 62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 12/1/2015 | 66JAA01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 11/9/2015 | 66JCA01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 5/8/2015 | 62OCA18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 1/26/2015 | 64MBY13CETRORELIX ACETATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 10/24/2014 | 54ADK05VITAMIN B12 (CYANOCOBALAMIN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/2/2014 | 64RCN21SOMATROPIN (HORMONE) | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 4/11/2013 | 62CCA99ANTI-HYPERTENSIVE N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/18/2012 | 62MDO01CAMPHOR (ANTI-PRURITIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/13/2011 | 66JCB01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/13/2011 | 66JCB01LEVOTHYROXINE SODIUM (THYROID HORMONE) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 9/9/2011 | 55RP99PHARMACEUTIC NECESSITIES, N.E.C. | 483DRUG NAME | New Orleans District Office (NOL-DO) |
| 6/25/2010 | 66VIP99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | New Orleans District Office (NOL-DO) |
| 6/9/2010 | 65RAN01CALCIUM CHLORIDE (REPLENISHER) | 16DIRECTIONS | New York District Office (NYK-DO) |
| 3/12/2009 | 63XCS83MANNITOL (DIAGNOSTIC AID) (DRUGS) | 75UNAPPROVED | New York District Office (NYK-DO) |
| 8/7/2007 | 62ODC18BISOPROLOL FUMARATE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | New York District Office (NYK-DO) |
| 6/17/2007 | 62YCB07MELOXICAM (ANTI-INFLAMMATORY, PART II) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/17/2007 | 62YCB07MELOXICAM (ANTI-INFLAMMATORY, PART II) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 5/22/2007 | 66VIP99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 8/8/2006 | 66PAS99ULTRAVIOLET SCREEN/SUNSCREEN N.E.C. | 16DIRECTIONS | New York District Office (NYK-DO) |
| 7/14/2006 | 64AAS08FORMALDEHYDE SOL (DISINFECTANT) | New York District Office (NYK-DO) | |
| 6/28/2005 | 54ACA90MULTIPLE VITAMINS (MVI-12 VITAMIN COMBO) (VITAMIN) | New Orleans District Office (NOL-DO) | |
| 10/15/2001 | 88LDTREAGENT, GENERAL PURPOSE | 118NOT LISTED | New Orleans District Office (NOL-DO) |
Frequently Asked Questions
What is Merck Kommanditgesellschaft auf Aktien's FDA import refusal history?
Merck Kommanditgesellschaft auf Aktien (FEI: 3002806906) has 68 FDA import refusal record(s) in our database, spanning from 10/15/2001 to 11/21/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Merck Kommanditgesellschaft auf Aktien's FEI number is 3002806906.
What types of violations has Merck Kommanditgesellschaft auf Aktien received?
Merck Kommanditgesellschaft auf Aktien has been cited for 7 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Merck Kommanditgesellschaft auf Aktien come from?
All FDA import refusal data for Merck Kommanditgesellschaft auf Aktien is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.